Biopharmaceuticals

Hong Kong – September 07, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.

Baltimore – September 07, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Drs. Osorio and Tufiño perform first Chondrograft implant procedure in Panama

Dr. Juan Osorio, the study's Principal Investigator, and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, carried out the bone-sparing, minimally invasive procedure. Dr. Tufiño noted the dedicated instrumentation set made the operation simple and efficient.

Thousand Oaks, Calif. – September 07, 2026 -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026.

Amgen's CFO and top medical and marketing executives will address investors

Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access, will represent Amgen at the conference.

Webcast access will be public and archived for 90 days

The presentation will be webcast live and made available to media, investors and the general public via Amgen's website under the Investors section. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will remain archived for replay for at least 90 days following the event.

Berlin – September 07, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.

Federal Ministry convenes stakeholders for September 3 dialogue

The Federal Ministry of Health has invited industry representatives to an in-depth discussion on Thursday, September 3, 2026, focused on harmonizing Germany's drug pricing and assessment framework. Pharma Deutschland, which represents roughly 400 member companies employing about 80,000 people in Germany, said it backs the continuation of the Pharma- und Medizintechnik Dialog but insists selective bureaucratic fixes cannot offset broader damage from recent legislation.

Daejeon – – September 07, 2026 -- Alteogen Inc. (KOSDAQ: 196170) has signed an option and license agreement with Novartis worth up to US$3,223 million, granting the Swiss drugmaker rights to develop subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 hyaluronidase.

Novartis secures multi-product option rights to ALT-B4 technology

Under the agreement, Novartis will hold multiple options to obtain exclusive rights to develop and commercialize subcutaneous formulations for several of its products using ALT-B4 (berahyaluronidase alfa). The enzyme, built on Alteogen's proprietary Hybrozyme platform, converts biologics normally delivered via intravenous infusion into faster, more convenient subcutaneous injections by temporarily depolymerizing hyaluronan in the extracellular matrix.

Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

Pivotal China trial clears statistical bar with wide margin over placebo

The registration study, conducted with Fosun Pharma affiliate JuveStar, enrolled 360 patients on active treatment and 120 on placebo, evaluating efficacy 84 days after one treatment cycle. Results showed a decisive statistical advantage across all measured endpoints, according to the companies.

Schlieren – September 07, 2026 -- NovaGo Therapeutics AG has closed a Series B financing round of CHF 24 million ($30 million), led by Neurimmune and Pureos, to fund a proof-of-concept trial for its anti-Nogo-A antibody in acute spinal cord injury.

The equity round drew participation from existing and new investors and was supplemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

NovaGo to enroll 120 patients across Germany, Spain and Switzerland

Proceeds will push the company's lead program, NG004, into a fully randomized, double-blind proof-of-concept study recruiting 120 acute spinal cord injury patients at centers in the three countries. NG004 is a fully human antibody designed to block Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system.

Singapore – September 07, 2026 -- Haier Biomedical (SHA: 688139) reported that revenue from pharmaceutical clients rose 23% year-on-year in the first half of 2026, while laboratory solutions revenue grew 19%, as the company unveiled new automated bio-storage and connected pharmaceutical technologies at the ISPE Singapore Conference & Exhibition 2026.

Automated -80°C storage system makes international exhibition debut

Held August 20-21 at Suntec Singapore, the event served as the venue for the first international showing of Haier Biomedical's automated ultra-low-temperature storage solution. The system combines automated -80°C storage with intelligent sample management to improve workflow efficiency and traceability for pharmaceutical companies and research organizations handling high-value samples.

Menlo Park – September 7, 2026 -- GRAIL, Inc. (Nasdaq: GRAL) will present at Morgan Stanley's 24th Annual Global Healthcare Conference in New York on Monday, September 14, at 11:30 a.m. ET.

GRAIL management to address investors at flagship healthcare investment event

The company's leadership team will speak directly to institutional investors and analysts at the closely watched conference, which draws major players across the healthcare and life sciences sector.

Live and archived webcast to be available via GRAIL's investor relations site

A live webcast of the presentation, along with a replay, will be accessible through the investor relations section of GRAIL's website. The archived version will remain available for at least 30 days following the event.

Pleasanton – September 07, 2026 -- Veeva Systems (NYSE: VEEV) has launched Veeva Falcon Safety, an AI agent product designed to streamline adverse event intake, case processing and follow-up for biopharmaceutical companies of all sizes, cutting costs while maintaining regulatory compliance.

Falcon Safety Integrates With Any E2B-Compatible System Across All Intake Channels

Beyond seamless integration with Veeva Safety, Falcon Safety will handle initial intake and follow-up management for any E2B-compatible safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance.

Veeva Positions Product as Part of Its Life Sciences AI Portfolio

Falcon Safety is part of Veeva AI, the company's line of artificial intelligence solutions built specifically for the life sciences sector.